GET DAILY SIGNALSPelthos Therapeutics (PTHS) Shows Solid Year-Over-Year Gains in Q3 Despite Slowing Growth
Key Takeaways
- Pelthos Therapeutics reported total revenue of $15.4 million for the third quarter of 2026, led by Zelsuvmi net product revenue of $15.2 million, up 114% year over year.
- Zelsuvmi units dispensed reached 12,384 in the quarter, a 4% sequential increase that marked a sharp slowdown from the 48% growth posted in the second quarter of 2026.
- The GAAP net loss narrowed to $7.9 million, or $2.04 per share, from $23.4 million in the prior quarter, helped by non-operating items.
- On a non-GAAP basis, the loss of $3.09 per share missed consensus estimates, while total revenue came in below the roughly $18 million Wall Street forecast.
- Commercial insurance coverage expanded to 127 million covered lives, and the company announced an October agreement to combine with Castle Creek Biosciences.
- Cash and cash equivalents stood at $17.7 million at quarter-end, with an additional $10.0 million drawn under its Horizon Technology Finance facility on October 30.
Why These Results Matter for PTHS
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on cutaneous, or skin-related, infectious disease treatments. Its lead product, Zelsuvmi (berdazimer) topical gel, is the first and only FDA-approved at-home therapy for molluscum contagiosum, a common viral skin infection affecting children. Because the stock's investment narrative is built almost entirely on Zelsuvmi's launch trajectory, each quarterly report is a crucial read on real-world demand, pricing, and payer access. The third quarter also carries added weight because management had guided toward a stable-to-growing prescription base after two quarters of rapid acceleration. With a transformative merger into rare-disease gene therapy on the horizon, I am watching closely whether the core commercial business can sustain momentum while the company pivots strategically. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Q3 Numbers
Pelthos Therapeutics reported third-quarter 2026 total revenue of $15.4 million, compared with roughly $7.1 million in the year-ago period. Zelsuvmi net product revenue was $15.2 million, up 114% year over year, while total Zelsuvmi units dispensed reached 12,384 across 4,942 unique prescribers, a 365% increase from the prior year. Sequentially, however, unit growth slowed to just 4%, down from 48% in the second quarter and 25% in the first quarter of 2026.
On the bottom line, the GAAP net loss was $7.9 million, or $2.04 per basic and diluted share, a significant narrowing from the $23.4 million loss in the second quarter. Much of that improvement stemmed from non-operating factors, including a gain on the fair value of convertible debt and the absence of a prior-quarter milestone expense. On a non-GAAP basis, the company posted a loss of $3.09 per share, which missed consensus expectations, while total revenue fell short of the roughly $18 million analyst forecast. Adjusted EBITDA was approximately negative $5.6 million, essentially flat versus the prior quarter. From what I see, the sequential slowdown in units is the key detail worth monitoring here.
How the Market Responded
The market's initial read on Pelthos's third-quarter results was cautious. A revenue miss combined with a first sequential plateau in Zelsuvmi unit demand overshadowed the headline year-over-year growth figures, and shares traded lower in the session following the release. Sentiment was already strained entering the quarter after an October announcement that the company would combine with Castle Creek Biosciences, an equity-funded transaction that raised concerns about dilution and the addition of late-stage clinical risk to a business that has not yet reached breakeven. Analysts noted that the launch curve flattening, with gross-to-net deductions rising to 31.5% from 29.6%, put renewed focus on the company's cash runway and its ability to reaccelerate prescription growth in the fourth quarter.
What to Watch Going Forward
Investors should watch whether Zelsuvmi prescription demand can reaccelerate into the fourth quarter, which will be the first test of recently expanded commercial coverage. Management added roughly 127 million covered lives, including a major pharmacy benefit manager contract effective October 1 with open access and no prior authorization. Early indicators were modestly encouraging, with October units marking the second-highest month on record, though only slightly above September.
Pricing dynamics will also matter. Gross-to-net deductions rose during the quarter and are expected to climb into the mid-30% range as new coverage takes effect. This means revenue growth will increasingly depend on volume rather than price.
Beyond Zelsuvmi, the company is preparing to launch two additional products, Xepi for impetigo targeted for the first quarter of 2027 and Xeglyze for head lice in mid-2027, which could diversify the top line. Finally, the pending Castle Creek Biosciences merger, expected to close by the end of the first quarter of 2027, will be a dominant factor shaping the investment thesis, given its dilution and the added clinical-stage risk it brings.
Using AI Tools for Deeper Analysis
In my own process, I frequently rely on Tickeron’s AI Screener to quickly filter biotechnology names and spot patterns in revenue growth or prescription trends that might otherwise take hours to uncover manually. It has become a practical part of how I cross-check quarterly updates like this one against peer performance and technical signals before forming a clearer view on names such as PTHS.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PTHS's RSI Oscillator remains in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTHS advanced for three days, in 107 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PTHS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PTHS turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In 25 of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTHS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PTHS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.874) is normal, around the industry mean (3.498). P/E Ratio (-0.327) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.470) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. PTHS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTHS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement